ESTIMATING THE COSTS OF DRUG SUPPLY FOR RARE DISEASES PATIENTS IN RUSSIA
Author(s)
Sura M1, Gerasimova K1, Omelyanovsky VV1, Avxentyeva M1, Tatarinov A2, Fedyaev D2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, 2Financial Scientific Research Institute of the Ministry of Finance of Russia, Moscow, Russia
OBJECTIVES: to estimate the costs of drug supply for registered rare diseases (RD) patients in Russia in 2013. METHODS: The study included two steps: 1) the analysis of the current situation with financing of drugs for RD patients in Russia in 2013 and 2) estimating the unmet needs - necessary weighted average costs (nWAC) for a pathogenetic pharmacotherapy of registered patients with RD in the same year. Number of registered patients with 24 RD listed in the Government Regulation of Russian Federation № 403 from April 26, 2012 was estimated for the studied year. Number of registered patients and actual financing has been received from the database of regional public health services. The nWAC for expensive pathogenetic pharmacotherapy of patients with 24 RD were calculated on the basis of standards of therapy and experts’ survey results. The current situation with financing of RD drugs in Russia in 2013 was compared with unmet needs (nWAC). RESULTS:
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PSY21
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Rare and Orphan Diseases